Vertex (VRTX) CSO Mark Bunnage sells 33 shares in pre-set 10b5-1 trade

Rhea-AI Filing Summary

Vertex Pharmaceuticals executive Mark E. Bunnage reported a small open-market sale of company stock. On this Form 4, the EVP and Chief Scientific Officer sold 33 shares of Common Stock at $453.45 per share and now directly holds 7,284 shares. The transaction was made under a pre-arranged Rule 10b5-1 trading plan entered into on November 26, 2025.

Insider Trade Summary 10b5-1

Net Seller: 33 shares ($14,964)

Net Sell 1 txn

Insider Bunnage Mark E.

Role EVP, Chief Scientific Officer

Sold 33 shs ($15K)

Type	Security	Shares	Price	Value
Sale	Common Stock	33	$453.45	$15K

Holdings After Transaction: Common Stock — 7,284 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares sold: 33 shares Sale price per share: $453.45 per share Shares held after transaction: 7,284 shares

3 metrics

Shares sold 33 shares Open-market sale of Common Stock on May 15, 2026

Sale price per share $453.45 per share Average transaction price for the reported sale

Shares held after transaction 7,284 shares Direct ownership following the Form 4 transaction

Key Terms

Common Stock, open-market sale, Rule 10b5-1

3 terms

Common Stock financial

"security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

open-market sale financial

"transaction_action: "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Rule 10b5-1 regulatory

"company approved trading plan under Rule 10b5-1"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bunnage Mark E.

(Last) (First) (Middle)

C/O VERTEX PHARMACEUTICALS INCORPORATED

50 NORTHERN AVENUE

(Street)

BOSTON MASSACHUSETTS 02210

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
VERTEX PHARMACEUTICALS INC / MA [ VRTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/15/2026		S(1)		33	D	$453.45	7,284	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to Dr. Bunnage's company approved trading plan under Rule 10b5-1, which was entered into on 11/26/2025.

Remarks:

	/s/ Christiana Stevenson, Attorney-in-Fact	05/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Vertex (VRTX) report for Mark E. Bunnage?

Vertex reported that Mark E. Bunnage, EVP and Chief Scientific Officer, sold 33 shares of Common Stock. The sale was an open-market transaction reported on Form 4, reflecting routine insider trading disclosure requirements.

At what price did Mark E. Bunnage sell Vertex (VRTX) shares?

Mark E. Bunnage sold 33 Vertex Common Stock shares at $453.45 per share. This price reflects the average transaction price for the reported open-market sale on the Form 4 insider trading report.

How many Vertex (VRTX) shares does Mark E. Bunnage hold after this sale?

After the reported sale, Mark E. Bunnage directly holds 7,284 shares of Vertex Common Stock. This post-transaction holding amount is disclosed in the Form 4 as total shares following the transaction.

Was the Vertex (VRTX) insider sale by Mark E. Bunnage under a 10b5-1 plan?

Yes. The Form 4 footnote states the transaction was made under Dr. Bunnage’s company-approved trading plan under Rule 10b5-1, which was entered into on November 26, 2025, indicating it was pre-arranged.

What role does Mark E. Bunnage hold at Vertex (VRTX)?

Mark E. Bunnage is an executive officer at Vertex, serving as Executive Vice President and Chief Scientific Officer. His status as an officer requires reporting transactions in company stock on Form 4.